John Seibyl

Active 1991–2025

121
Papers
25,691
Citations
84
h-index
117
i10-index

Citations

Citations per year for John Seibyl1986: 1 citations1992: 2 citations1993: 6 citations1994: 14 citations1995: 19 citations1996: 34 citations1997: 99 citations1998: 74 citations1999: 129 citations2000: 180 citations2001: 199 citations2002: 238 citations2003: 240 citations2004: 223 citations2005: 241 citations2006: 217 citations2007: 250 citations2008: 190 citations2009: 212 citations2010: 134 citations2011: 154 citations2012: 174 citations2013: 150 citations2014: 141 citations2015: 182 citations2016: 172 citations2017: 209 citations2018: 198 citations2019: 627 citations2020: 764 citations2021: 772 citations2022: 712 citations2023: 626 citations2024: 1,124 citations2025: 674 citations2026: 45 citations1987–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,416 citing papers, 27.7% of this breakdownUnited Kingdom: 1,118 citing papers, 9.1% of this breakdownGermany: 897 citing papers, 7.3% of this breakdownChina: 705 citing papers, 5.7% of this breakdownCanada: 625 citing papers, 5.1% of this breakdownItaly: 502 citing papers, 4.1% of this breakdownSweden: 489 citing papers, 4% of this breakdownNetherlands: 428 citing papers, 3.5% of this breakdownSpain: 389 citing papers, 3.1% of this breakdownFrance: 389 citing papers, 3.1% of this breakdownSwitzerland: 316 citing papers, 2.6% of this breakdownAustralia: 304 citing papers, 2.5% of this breakdown
0%27.7%Other 22.2%

Fields

  • Medicine62.9%
  • Neuroscience22.2%
  • Biochemistry, Genetics and Molecular Biology5.5%
  • Psychology4.5%
  • Computer Science2.3%
  • Health Professions0.4%
  • Other2.2%

Topics

  • Parkinson's Disease Mechanisms and Treatments10.7%
  • Neurological disorders and treatments7%
  • Alzheimer's disease research and treatments6.8%
  • Dementia and Cognitive Impairment Research5.6%
  • Neurotransmitter Receptor Influence on Behavior4.2%
  • Functional Brain Connectivity Studies3.4%
  • Other62.3%

Coauthors

All papers

Open in search
  1. The Parkinson Progression Marker Initiative (PPMI)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith A. Hawkins, Jamie L. Eberling, Deborah W. Brooks, David Russell, Laura Leary, Stewart A. Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David G. Standaert, Stephanie Guthrie, Robert A. Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi-Ann Thomas, Irene Hegeman Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly A. Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltán Mari, Melissa Gerstenhaber, David J. Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor D. Grachev, Kim P. Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, Tony W. Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor - Progress in Neurobiology 2011 cited by 1,915

  2. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Neurology 2023 cited by 693

  3. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Weintraub, Yuge Xiao, Andrew Siderowf, Billy Dunn, Kenneth Marek - The Lancet Neurology 2024 cited by 563

  4. CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

    Authors: , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2018 cited by 829

  5. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Clinical and Translational Neurology 2018 cited by 686

  6. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2015 cited by 609

  7. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kai Bötzel, Joseph Claßen, Peter Bartenstein, Victor L. Villemagne, Johannes Levin, Günter U. Höglinger, Alexander Drzezga, John Seibyl, Osama Sabri - JAMA Neurology 2020 cited by 253

  8. Tau deposition patterns are associated with functional connectivity in primary tauopathies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jost J. Rumpf, Matthias L. Schroeter, Joseph Claßen, Victor L. Villemagne, John Seibyl, Andrew Stephens, Edward B. Lee, David G. Coughlin, Armin Giese, Murray Grossman, Corey T. McMillan, Ellen Gelpí, Laura Molina‐Porcel, Yaroslau Compta, John C. van Swieten, Laura Donker Laat, Claire Troakes, Safa Al‐Sarraj, John Robinson, Sharon X. Xie, David J. Irwin, Sigrun Roeber, Jochen Herms, Mikael Simons, Peter Bartenstein, Virginia M. Lee, John Q. Trojanowski, Johannes Levin, Günter U. Höglinger, Michael Ewers - Nature Communications 2022 cited by 108

  9. Targeting Prodromal Alzheimer Disease With Avagacestat

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Neurology 2015 cited by 233

  10. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2020 cited by 201

  11. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 257

  12. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

    Authors: , , , , , , , , , , , , - Journal of Nuclear Medicine 2016 cited by 258

  13. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Alzheimer s Disease 2017 cited by 217

  14. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2018 cited by 205

  15. Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study

    Authors: , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2019 cited by 200

  16. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

    Authors: , , , , , , , , , , - The Lancet Neurology 2011 cited by 586

  17. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

    Authors: , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2012 cited by 399

  18. Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression

    Authors: , , , , , , , , , , - Movement Disorders 2021 cited by 66

  19. MRI-based measurement of hippocampal volume in patients with combat- related posttraumatic stress disorder

    Authors: , , , , , , , , , - American Journal of Psychiatry 1995 cited by 1,611

  20. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort

    Authors: , , , , , , , - JAMA Neurology 2017 cited by 198

  21. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease

    Authors: , , , , , , , , - Brain 2015 cited by 219

  22. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

    Authors: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1996 cited by 1,294

  23. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , John Seibyl, Susan Mendick, Norbert Schuff, Chelsea Caspell, Liz Uribe, Eric D. Foster, Katherine B. Gloer, Jon Yankey, Arthur W. Toga, Karen Crawford, Paola Casalin, Giulia Malferrari, Brit Mollenhauer, Douglas Galasko, Andrew Singleton, Keith A. Hawkins, David Russell, Stewart A. Factor, Penelope Hogarth, David G. Standaert, Robert A. Hauser, Joseph Jankovic, Matthew Stern, Lana M. Chahine, James B. Leverenz, Samuel Frank, Irene Richard, Klaus Seppi, Holly A. Shill, Hubert Fernandez, Daniela Berg, Isabel Wurster, Douglas Galasko, Zoltan Mari, David J. Brooks, Nicola Pavese, Paolo Barone, Stuart Isaacson, Alberto J. Espay, Dominic B. Rowe, Melanie Brandabur, James W. Tetrud, Grace Liang, Álex Iranzo, Eduardo Tolosa, Laura Leary, C Riordan, Linda Rees, Alicia Portillo, Art Lenahan, Karen Williams, Stephanie Guthrie, Ashlee Brooke Rawlins, Sherry Harlan, Christine Hunter, Baochan Tran, Abigail Darin, Carly Linder, Marne Baca, Heli Venkov, Cathi-Ann Thomas, Raymond James, Cheryl Deeley, Courtney Bishop, Fabienne Sprenger, Diana Willeke, Sanja Obradov, Jennifer Mule, Nancy Monahan, Katharina Gauss and 98 more - Neurology 2017 cited by 152

  24. Signs and Artifacts in Amyloid PET

    Authors: , , , , - Radiographics 2018 cited by 89